纵向治疗中循环肿瘤DNA作为癌症患者实时动态风险监测的生物标志物:EP-SEASON研究

文章预览

SCI 12 August 2024 Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study （Cancer Cell；IF：48.8） Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, Zhen ZC, Li WF, Tang LL, Mao YP et al: Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell 2024. Correspondence to: majun@sysucc.org.cn (J.M.), chenyup1@sysucc.org.cn (Y.-P.C.), zhougq@sysucc.org.cn (G.-Q.Z.), sunying@sysucc.org.cn (Y.S.) SUMMARY摘要 Recurrence risks of cancer patient can change during treatment as a result of treatment-related tumor evolution. However, biomarkers that can monitor these changes are lacking. Here, we investigated whether tracking circulating tumor DNA (ctDNA) dynamics through liquid biopsy can inform real-time recurrence risk. Nasopharyngeal Carcinoma (NPC) provides an ideal model where cell-free Epstein-Barr virus (EBV)D ………………………………